News & Updates

Individuals who have contracted COVID-19 at increased risk of developing irritable bowel syndrome (IBS) compared with those who have not been infected, as reported in a study.

In vaccinated adults with COVID-19 who are at higher risk of adverse outcomes, treatment with molnupiravir in addition to usual care falls short of reducing the rates of hospitalizations and deaths, as shown by the results of the PANORAMIC study.

In a functional assessment of post-COVID long-term sequelae, individuals suffering from long COVID (having at least one symptom of post-COVID-19 syndrome) had poorer quality of life (QoL) than those unaffected by the syndrome.

Use of medicines for COVID-19 during pregnancy is higher in patients with more severe disease, according to a study. In addition, a trend towards increased corticosteroids use has been observed and appears to be consistent with changing guidelines.

Immunotherapy with MV-140 (Uromune) successfully prevents urinary tract infections (UTIs) in patients suffering from recurrent UTIs, suggest the results of a prospective study presented at the 38th Annual EAU Congress (EAU 2023).

Treatment with valaciclovir leads to efficacious suppression of Epstein-Barr virus (EBV), having the potential to reduce the sputum inflammatory cell infiltrate, in patients with chronic obstructive pulmonary disease (COPD), according to data from the EViSCO study.